costs of caring for the 4.5 million Americans with Alzheimer disease are at least $100 billion annually 4 .
It is estimated that more than 70% of people with Alzheimer disease live at home, where family and friends provide the majority of care, placing physical and emotional stress on caregivers. As a result, the caregivers are themselves at risk of psychiatric and physical morbidity and, according to the Alzheimer's Association, one in eight caregivers of individuals with Alzheimer disease becomes ill or injured, and one in three uses medication for problems related to caregiving 5 .
By 2030, when the baby boom generation is more than 65 years old, the number of Americans with Alzheimer disease is expected to soar to levels that may exceed the ability of the government to absorb the added cost. According to a report commissioned by the Alzheimer's Association, Medicare costs for beneficiaries with Alzheimer disease are expected to increase 75% from $91 billion in 2005 to $160 billion in 2010. Furthermore, Medicaid expenditures on residential dementia care were reportedly $21 billion in 2005 and expected to increase by 14% to $24 billion in 2010 (Fig. 2) 6 . According to the Alzheimer's Association, however, the advent of effective treatments that can delay the onset of Alzheimer disease for just five years could save $50 billion in annual healthcare costs. Hence, governments and Alzheimer disease associations have made it their goal to delay the disabling symptoms of the disease and eventually prevent it. To support this aim, the government's commitment to research has grown dramatically in recent years. For example, in fiscal year 2005, the American government estimates spending of approximately $647 million for Alzheimer disease research 7 .
Diagnosis and initial care
Diagnosis rates are generally low, averaging around 60% in developed nations, but vary widely according to healthcare policies and guidelines in different countries. Definitive diagnosis of Alzheimer disease can only be performed by examining the neuropathological features of the disease-amyloid plaques and neurofibrillary tangles-at autopsy. Nevertheless, in the day-to-day clinical setting, a variety of methods are used, and research has suggested that this can be considered 87% effective compared with autopsy 8 . Early diagnosis is beneficial for the patients, as they can
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be treated early and any comorbidities can be monitored, as well as for their families, who can receive additional support. In developed countries, primary care is the point of initial diagnosis; individuals may subsequently be referred to a neurologist to confirm diagnosis and for treatment. Some neurologists refer patients for a brain scan, but the norm is for patients to be assessed against standard clinical criteria that take into account patient age, cognitive testing (such as the MiniMental State Exam (MMSE) or Mini-Cog), and functional and behavioral testing (such as the Dementia Severity Rating Scale). The National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCD-ADRDA) criteria use this information to give a diagnosis of 'probable' or 'possible' Alzheimer disease. Criteria from the Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) can also be used. In clinical trials, it is often the MMSE that is used as a primary endpoint, although it is arguable whether this endpoint is sensitive or robust enough, as the test was not designed for repeated use.
To proceed to treatment, individuals are assigned to stages of Alzheimer disease, which are most easily defined by their MMSE score. Individuals rating with 'mild' Alzheimer disease are able to perform activities of daily living independently, have difficulty with memory and learning, and have mild personality changes. They then progress to 'moderate' and 'severe' Alzheimer disease, which are characterized by increased dependence on a caregiver, impairment of language and memory and a short attention span. 'Profound' and 'terminal' Alzheimer disease precede death as the disease worsens.
Despite the evident insufficiencies in current Alzheimer disease diagnostic techniques, we believe diagnosis is unlikely to change profoundly in the future. Telephone-and selfdiagnosis technologies are available but are not thought to be adequate or particularly useful. Laboratory tests using urine or other patient samples are also in their infancy, as clinically useful and robust biomarkers for disease have yet to be developed.
Current treatment of Alzheimer disease
Whereas diagnosis of Alzheimer disease can be performed with some certainty, the underlying pathophysiology is still not well understood. A variety of pharmaceutical approaches, targeted at several disease hypotheses, are now under investigation. However, currently available treatment options are limited and, when compared with other therapeutic areas, differentiation between these options in terms of efficacy is minimal.
There are currently two classes of drugs approved for the treatment of symptoms of late-onset or sporadic Alzheimer disease ( Table 1) . Acetylcholinesterase (AChE) inhibitors prolong the action of acetylcholine in the synapse by preventing its breakdown. This strategy results in improvements of cognition, mood and behavior. N-methyl-D-aspartate (NMDA) receptor antagonists are believed to work by helping to regulate levels of the neurotransmitter glutamate.
AChE inhibitors. Treatment practices depend on the patients' age and stage of disease. The AChE inhibitors are widely considered to be first-line treatment for the cognitive symptoms of dementia associated with Alzheimer disease and are indicated for the mild and moderate stages. The AChE inhibitor class of drugs is represented by donepezil (Aricept, Eisai/Pfizer), rivastigmine (Exelon, Novartis) and galantamine (Razadyne, Johnson & Johnson). Multiple studies of AChE inhibitors have shown that they are generally well tolerated. If side effects do occur, they commonly include nausea, vomiting, loss of appetite, diarrhea and bradycardia. Nevertheless, they show modest clinical benefits in the earlier stages of Alzheimer disease 9 . On the other hand, there is evidence that AChE inhibitors, in addition to providing symptomatic relief, may slow disease progression 10 . This, however, remains controversial.
Tacrine (Cognex) was the first cholinesterase inhibitor, approved in 1993, but is rarely prescribed today because of side effects, including a risk of liver damage. In contrast, one of the first AChE products to enter the market, Aricept has performed exceptionally well and, despite competition from Razadyne and Exelon, Aricept is expected to remain the leading product by sales in this class, owing to a more convenient dosing schedule (once daily) and continued strong comarketing support from Pfizer. We predict that Aricept will maintain a global market share of more than 40% until 2010 (Box 1).
Like Aricept, Exelon is an AChE inhibitor indicated for the treatment of mild to moderate Alzheimer disease. Exelon has performed well in this fast-growing market. To drive future growth, Novartis has instigated an extensive clinical development program including a head-to-head trial against Aricept, and is also looking to expand the indication base to include mild cognitive impairment, vascular dementia, Lewy body dementia, moderate to severe Alzheimer disease and Parkinson disease. US sales are expected to enter a steady decline when the key US patent expires in 2007. We predict sales in the rest of the world to grow, however, driven by line extension programs. In January 2006, the European Union's Committee for Medicinal Products for Human Use gave a positive opinion for the use of Exelon for dementia associated with Parkinson disease, following an appeal by Novartis against an earlier negative opinion.
Reminyl Although memantine is indicated for the later stages of the disease, there is evidence that there is significant off-label use, particularly in combination with an AChE inhibitor for mild and moderate Alzheimer disease in the US. Clinical trials designed to seek approval for mild to moderate Alzheimer disease are ongoing, and a successful approval would give the product a broad label covering mild to severe disease states. In addition, the potential for combination therapy is being explored, and preliminary data suggest that memantine in combination with Aricept is superior to Aricept alone in the treatment of moderate to severe Alzheimer disease 14 . Furthermore, Daiichi-Sankyo is developing memantine for the Japanese market, where it is currently in phase 3 clinical development for the treatment of severe Alzheimer disease.
Emerging therapies
AChE inhibitors and NMDA antagonists will continue to form the backbone of symptomatic relief of dementia in Alzheimer disease for the near term. However, none of the currently approved drugs stops the underlying degeneration of brain cells or reverses the progression of Alzheimer disease. Furthermore, about 30-40% of individuals with Alzheimer disease do not respond to AChE inhibitors, and approximately 29% of individuals treated with AChE inhibitors leave clinical trials because of adverse events, compared to 18% of those from the placebo group 15 . Reflecting the dissatisfaction with current treatment options, current research and development efforts are aimed at addressing the etiology of the disease, and a significant number of candidates are currently in development for treatment of Alzheimer disease.
The molecules and processes being explored as targets of potential new therapies for Alzheimer disease reflect several leading hypotheses on the underlying causes of the disorder. They include amyloid plaque deposition, formation of neurofibrillary tangles and neuroinflammation. The variety of therapeutic approaches being researched may foretell a market in which individuals are treated optimally with drug combination therapy ( Table 2) .
Arguably, the most exciting drugs in development are targeted at the amyloid-β peptide, the main component of amyloid plaques. It is thought that if this type of drug can work early in the disease, it could act as a disease modifier and delay or prevent progression to later stages. If these drugs can deliver on their promise, they will be highly valuable. Although the amyloid hypothesis is well supported, some controversy persists regarding the existence of a clinical link and was the third AChE inhibitor to enter the market for the treatment of mild to moderate Alzheimer disease. Despite few differentiating features and a relatively late entry, uptake has been impressive, aided by Johnson & Johnson's marketing skills. In the future, Razadyne is expected to generate sustained growth in the short term. We predict, however, that sales of Razadyne will decline steadily once US patent protection is lost in 2008.
Despite the phenomenal growth of AChE inhibitors, some concerns remain over the relatively modest efficacy of the class as a whole, and little evidence exists to support continued use into advanced stages 11 . In this regard, the UK's National Institute of Clinical Excellence (NICE) is due to publish its final recommendation on the use of Alzheimer disease drugs this summer. It is anticipated that the institute will only recommend the use of AChE inhibitors for individuals with moderate Alzheimer disease and will state that there is not sufficient evidence to advocate the prescription of mematine (see below). NICE's concerns echo those of many experts that, when considered rationally, these drugs are simply not effective enough to warrant widespread prescription.
Nevertheless, AChE inhibitors continue to be investigated in Alzheimer disease clinical trials with a view to expanding their labels to encompass mild cognitive impairment, and milder and/or more severe forms of Alzheimer disease. Furthermore, uptake of the AChE inhibitors continues to grow steadily year on year, primarily through expanded market volume driven by the lack of alternative treatments, the increase in the elderly population and earlier initiation of treatment.
For people with mild to moderate Alzheimer disease, antioxidants such as vitamin E are often recommended in combination with AChE inhibitors, and their use is often continued into Other products
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between reduction in amyloid-β and symptom improvement (see page 723), and certain evidence suggests alternative processes as the prime cause of Alzheimer disease.
The most advanced drug targeting amyloid-β is tramiprosate (Alzhemed), being developed by Neurochem. This small molecule, which can be taken orally, binds soluble amyloid-β, preventing it from aggregating into plaques. Currently in phase 2 clinical trials, the drug seemed to have a good safety profile, showed moderate evidence of efficacy and reduced amyloid-β levels. Phase 3 trials in Europe and North America are now ongoing, with more than 1,000 participants with mild to moderate Alzheimer disease currently taking AChE inhibitors. The trial will track participants for 18 months, and subjects completing this part of the trial will be asked to continue in an open-label section of the study. This is noteworthy, as evidence of disease modification (such as changes in brain volume) may require a longer time frame compared with trials using cognitive measures as endpoint. Initial results from this trial are expected early in 2007.
An amyloid-β-lowering agent named R-flurbiprofen (Flurizan), developed by Myriad Genetics, is in phase 3 trials involving participants with mild Alzheimer disease. Its mechanism of action is not well understood and, although the racemic mixture of flurbiprofen is an established nonsteroidal anti-inflammatory drug (NSAID), the R isomer is not thought to have cyclooxygenase activity. In phase 2 trials, Flurizan was well tolerated but it did not meet its primary endpoint using ADAS-Cog (Alzheimer Voyager Pharmaceuticals is developing extended-release leuprolide acetate (Memryte) for mild to moderate Alzheimer disease, which is currently in phase 3 trials. Leuprolide affects levels of luteinizing hormone, which modulate cognition and amyloid-β deposition. Results from phase 2 trials in female participants with mild to moderate Alzheimer disease did not meet the primary endpoint efficacy measurements of ADAS-Cog and ADCSCGIC (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change), but did show an effect in participants receiving high-dose leuprolide and additional AChE inhibitors. Results from phase 2 trials in male participants are expected later this year, and phase 3 results from two 56-week trials are expected in 2007.
As a follow up to memantine (Namenda), Merz and Forest Labs are developing neramexane, another NMDA receptor antagonist. Like Namenda, neramexane is being studied in individuals with moderate to severe Alzheimer disease, but it did not meet its primary endpoint efficacy measurements of SIB (Severe Impairment Battery) and ADCS-ADLsev (ADCS-ADL severe subset) when tested in phase 3 trials in combination with AChE inhibitors (although Namenda did not work in individuals with mild to moderate disease). A second phase 3 trial as monotherapy showed statistical significance for neramexane in individuals with moderate to severe disease; the primary endpoint of this trial was efficacy measurement of ADCS-ADL, and further phase 3 studies are planned. As Namenda's patent is expected to expire in 2010, neramexane may be an early follow-on product and must show a level of differentiation over Namenda if it is to succeed. Nonetheless, with a number of other indications also in development for neramexane (including neuropathic pain, tinnitus and alcohol dependence), it is clear there is commitment from Forest and Merz behind it.
Two 5-HT1A agonists are in phase 3 trials for Alzheimer disease. Targeting serotonin receptors in Alzheimer disease may alleviate some symptoms of Alzheimer disease because a decline in serotonin function is associated with cognitive decline in people with the disease 16 . Lecozotan (Wyeth) is under investigation for treatment of symptoms associated with cognitive deficits in individuals with mild to moderate Alzheimer disease, and Xaliproden (Sanofi-Aventis) is being investigated in a large trial of individuals with mild to moderate Alzheimer disease, although it has had a checkered history, with a number of already-failed indications such as anxiety, multiple sclerosis and neuropathy.
Developing drugs for Alzheimer disease is fraught with difficulties in predicting efficacy in large-scale trials. Interestingly, Targacept and its new licensee AstraZeneca chose to initially gather evidence for their nicotinic acetylcholine agonist ispronicline for indications such as age-associated memory impairment and mild cognitive impairment, for which trials can be easier to perform and which are often considered 
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precursors to Alzheimer disease. It is then their intention to test the drug, now in phase 2 clinical trials, in Alzheimer disease itself, following 'proof of concept' in these initial indications. In our opinion, the most exciting drug in development is Elan and Wyeth's bapineuzumab (AAB-001), a humanized monoclonal antibody against amyloid-β, which is in phase 2 trials. As part of an alliance investigating a number of opportunities including the amyloid-β vaccine ACC-001, Elan and Wyeth are concentrating on immunotherapeutic strategies for Alzheimer disease in the hope that they will lead to a truly disease-modifying drug. Evidence of efficacy with AAB-001 has already been obtained (Black, R.S. et al., presented at 9th Annual Geneva Springfield Symposium on Advances in Alzheimer's Therapy in Geneva, Switzerland). These drug candidates may also carry the highest risk, however; the highest dose of AAB-001 has now been discontinued owing to transient abnormalities observed through brain imaging (Black, R.S. et al., presented at 9th Annual Geneva Springfield Symposium on Advances in Alzheimer's Therapy in Geneva, Switzerland). An earlier candidate drug developed to trigger an immune response against amyloid-β, AN-1792, was also discontinued owing to cases of encephalitis. 17 
Conclusion
As population demographics shift and the number of individuals with Alzheimer disease continues to increase, the challenge to develop targeted, effective treatments and our ability to recognize early symptoms and intervene to prevent disease progression will become more crucial. Although current treatments for Alzheimer disease have witnessed phenomenal sales growth and will continue to do so, they have provided only modest symptomatic relief, and much of their success appears to be borne of the significant unmet need, as highlighted by the UK's NICE appraisal. Over the past 15 years, research on Alzheimer disease has increased our understanding of the underlying mechanisms of disease progression and provided new targets for drug validation, generating new hope for the future. It remains to be seen, however, whether any of the new drugs in clinical trials will truly modify disease. Furthermore, clinical development in this field is particularly complex, expensive and highly uncertain in terms of predicting success early in development, choosing appropriate clinical measurements and obtaining results for successful approval. Nevertheless, given the unmet need, we anticipate that there are considerable opportunities within the Alzheimer disease market, and truly disease-modifying drugs have the potential to expand it further.
